Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $92

PTC Therapeutics, Inc. -4.22%

PTC Therapeutics, Inc.

PTCT

65.67

-4.22%

Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ: PTCT) with a Overweight and raises the price target from $90 to $92.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via